The treatment of people with serious diseases in Russia is provided by the state, for this it purchases drugs for budgetary funds. However, innovative expensive drugs do not always provide the claimed benefits, said “Parliamentskaya Gazeta” Doctor of Medical Sciences, State Duma Deputy Airat Farrakhov.
“The current public procurement system does not allow cost reduction in this case, so we propose to apply the risk-sharing principle to pay for the drug if its efficacy is clear. This will save the budget and be spent on new patients,” he said.
He noted that currently there are no provisions in the law on the contract supply system that would allow the buyer to enter into contracts for the supply of medicines with additional obligations to the supplier or manufacturer.
“Therefore, government customers cannot get more favorable contractual terms and are forced to purchase expensive drugs under the state guarantee program of free medical care for citizens, even if these drugs do not benefit patients,” said the MP.
Farrakhov proposed to supplement the law with a new clause that would allow the state client to conclude a contract for the supply of original or reference drugs without registered analogues, and share the risks of treatment failure.
Earlier, it was reported that NUST MISIS experts were with colleagues from the University of Chemistry-Technology. DI. Mendeleev work A way to increase the effectiveness of drugs using nanoparticles.